Evoke Pharma’s stock skyrockets on impressive Gimoti data—what this means for diabetic gastroparesis patients

Shares in Evoke Pharma experienced an extraordinary 70% surge following the release of new, promising data on their flagship product, Gimoti. This growth marks a ... Read More